



12

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Changyou Zhou, et al . Art Unit:
Serial No. : 10/528,293 Case No.: 21055P . 1625
Filed : March 16, 2005 . Examiner:
For : PIPERIDINYL-ALPHA-AMINOAMIDE MODULATORS . C. Chang
OF CHEMOKINE RECEPTOR ACTIVITY .

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference. A copy of the cited reference is enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By William J. Burger Date 8-29-2007


This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed before issuance of a First Office Action and within three months of a communication from a foreign patent office citing the reference. No fee is believed to be due.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By 
James L. McGinnis
Reg. No. 34,387
Attorney for Applicants

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0641

Date: August 29, 2007

AUG 31 2007

Use as many sheets as necessary)

Application Number	10/528,293
Filing Date	March 16, 2005
First Named Inventor	Changyou Zhou, et al.
Group Art Unit	1625
Examiner Name	Chang
Attorney Docket Number	21055P

Sheet

of

1

Attorney Docket Number	21055P
------------------------	--------

[illegible][illegible]

Examiner
Signature

Date
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/28/2007